Open AccessSafety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
Author(s) -
Jake A Ruddy,
Brian J. Boyarsky,
Justin R. Bailey,
Andrew H. Karaba,
Jacqueline Garonzik-Wang,
Dorry L. Segev,
Christine M. Durand,
William A Werbel
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000003017
Subject(s) - vaccination , antibody , virology , covid-19 , medicine , antibody response , adverse effect , messenger rna , immunology , human immunodeficiency virus (hiv) , lentivirus , viral disease , biology , outbreak , gene , infectious disease (medical specialty) , biochemistry , disease
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.